Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + melphalan + tamoxifen
- Development stage
- Discontinued
- Lead developer
- NSABP Foundation
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy and endocrine therapy regimen used historically for breast cancer treatment. This regimen combines fluorouracil (an antimetabolite that interferes with DNA synthesis), melphalan (an alkylating agent), and tamoxifen (an antiestrogen/selective estrogen receptor modulator). Clinical studies have shown potential antagonistic interactions between these agents, particularly between tamoxifen and the cytotoxic effects of melphalan and fluorouracil.
02
Targets
ESR1 (ERα)ESR2 (ERβ)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + melphalan + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + melphalan + tamoxifen.